Ribosome biogenesis-related gene signature predicts prognosis and immune landscape in glioma and identifies UTP20 as a therapeutic target
The RBRGs signature was successfully developed and validated as an independent prognostic biomarker and predictor of therapeutic response in glioma, highlighting its extensive association with tumor heterogeneity. Furthermore, this study identified UTP20 as a key oncogenic driver that facilitates glioma progression.
Authors
- Xinxin Si (ORCID: https://orcid.org/0000-0003-0393-4223)
- Xiaolong Tang (ORCID: https://orcid.org/0000-0003-2201-5812)
- Yongshuo Liu (ORCID: https://orcid.org/0000-0001-8190-0139)
- Yanfang Cui (ORCID: https://orcid.org/0000-0002-1041-9097)
- Yunfeng Li (ORCID: https://orcid.org/0000-0003-2659-8074)
- Wenhui Zhao (ORCID: https://orcid.org/0000-0002-7215-4610)
- Yanbin Dong (ORCID: https://orcid.org/0000-0001-5561-1683)
Institutions
- Shandong University of Aeronautics (CN)
- Xuzhou Medical College (CN)
- Lianyungang Oriental Hospital (CN)
- The First People’s Hospital of Lianyungang (CN)
- Shandong First Medical University (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1680667
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00